{"title":"第二部分:药品营销的立法环境","authors":"Mickey C. Smith","doi":"10.3109/J058V18N01_03","DOIUrl":null,"url":null,"abstract":"ABSTRACTIn Part II, the editor looks at the Kefauver, Nelson, and Kennedy drug industry hearings and the legislation resulting from the hearigs. Portions of the hearings are prestented, along with analysis and discussion of the ultimate effects of the hearings on the pharmaceutical industry and pharmacy. The editor then offers a defense of pharmaceutical marketing and some possibilities for its future.","PeriodicalId":16734,"journal":{"name":"Journal of Pharmaceutical Marketing & Management","volume":"63 1","pages":"17-89"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Part II: The Legislative Environment of Pharmaceutical Marketing\",\"authors\":\"Mickey C. Smith\",\"doi\":\"10.3109/J058V18N01_03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACTIn Part II, the editor looks at the Kefauver, Nelson, and Kennedy drug industry hearings and the legislation resulting from the hearigs. Portions of the hearings are prestented, along with analysis and discussion of the ultimate effects of the hearings on the pharmaceutical industry and pharmacy. The editor then offers a defense of pharmaceutical marketing and some possibilities for its future.\",\"PeriodicalId\":16734,\"journal\":{\"name\":\"Journal of Pharmaceutical Marketing & Management\",\"volume\":\"63 1\",\"pages\":\"17-89\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Marketing & Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/J058V18N01_03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Marketing & Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/J058V18N01_03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Part II: The Legislative Environment of Pharmaceutical Marketing
ABSTRACTIn Part II, the editor looks at the Kefauver, Nelson, and Kennedy drug industry hearings and the legislation resulting from the hearigs. Portions of the hearings are prestented, along with analysis and discussion of the ultimate effects of the hearings on the pharmaceutical industry and pharmacy. The editor then offers a defense of pharmaceutical marketing and some possibilities for its future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
